|
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of novel drugs. The company has obtained marketing authorization for sac-TMT, tagitanlimab, Cetuximab N01, and trastuzumab botidotin, and has filed a New Drug Application for Lunbotinib Fumarate Capsules. Its therapeutic focus includes breast cancer, non-small cell lung cancer, gastrointestinal cancers, gynecological tumors, and genitourinary cancers. The company operates a commercialization team covering marketing, sales, distribution, and medical affairs in China. It pursues a global strategy through out-licensing and collaboration agreements to leverage partners' capabilities for international clinical development and commercialization. The company also explores in-licensing opportunities for new drug candidates and technologies to expand its pipeline. Key subsidiaries include KLUS PHARMA INC. and Sichuan Kelun-Biotech Targeted Biologics Engineering Research Center Co., Ltd. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage kelun-biotech.com |
| Sector Healthcare | IR page — | |
|
Tags
oncology, antibody-drug conjugates, targeted therapy, novel drugs, clinical development, biopharmaceuticals, breast cancer, lung cancer, gastrointestinal cancers, out-licensing, sac-TMT, tagitanlimab, Cetuximab N01, trastuzumab botidotin, Lunbotinib Fumarate Capsules, KLUS PHARMA INC., Sichuan Kelun-Biotech Targeted Biologics Engineering Research Center Co. Ltd., Sichuan Kelun Doosan Biotechnology Co. Ltd., Chengdu Kelun Jingchuan Technology Co. Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 74.61B |
| Market cap (USD) | $ 9.508B |
| P/E | 419.25 |
| PEG | — |
| P/BV | 15.27 |
| P/S | 30.39 |
| P/OCF | 119.23 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.31% |
| Returns | |
|---|---|
| ROE | -9.3% |
| ROI | -7.8% |
| ROIC | -5.4% |
| Profit margin | -18.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -61.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Sichuan Kelun-Biotech Biopharm Co Ltd
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| MCHS | 1.50% | 6,700 | $ 372.676K | Jun 30, 2026 |
| NBCE | 0.99% | 2,850 | $ 180.778K | Aug 31, 2026 |
| MINV | 0.83% | 27,800 | $ 1.546M | Jun 30, 2026 |
| JSTC | 0.02% | 894 | $ 50.136K | Nov 17, 2026 |
| DFAE | 0.01% | 21,900 | $ 1.279M | Nov 12, 2026 |
| DFEM | 0.01% | 15,500 | $ 904.948K | Nov 12, 2026 |
| DFSE | 0.00% | 200 | $ 11.677K | Nov 12, 2026 |
| DFAX | 0.00% | 1,800 | $ 105.091K | Nov 12, 2026 |